參考文獻 |
1. Jarzembowski, J. A., and M. B. Young. 2008. Nontuberculous mycobacterial infections. Arch Pathol Lab Med 132:1333-1341.
2. Guerardel, Y., E. Maes, V. Briken, F. Chirat, Y. Leroy, C. Locht, G. Strecker, and L. Kremer. 2003. Lipomannan and lipoarabinomannan from a clinical isolate of Mycobacterium kansasii: novel structural features and apoptosis-inducing properties. J Biol Chem 278:36637-36651.
3. Ting-Shu Wu 2, Chia-Chen Lu 1 and Hsin-Chih Lai 1. 2009. Current Situations on Identification of Nontuberculous Mycobacteria J Biomed Lab Sci 21:6.
4. Ellis, S. M. 2004. The spectrum of tuberculosis and non-tuberculous mycobacterial infection. Eur Radiol 14 Suppl 3:E34-42.
5. Razavi, B., and M. G. Cleveland. 2000. Cutaneous infection due to Mycobacterium kansasii. Diagn Microbiol Infect Dis 38:173-175.
6. 1994-2010. Mycobacterium Kansasii.
7. Wolinsky, E. 1992. Mycobacterial diseases other than tuberculosis. Clin Infect Dis 15:1-10.
8. Koneman EW, Allen SD, and J. WM. 1992. Mycobacteria. In: Color atlas and textbook of diagnostic microbiology. JB Lippincott, Philadelphia.
9. Wu, T. S., H. S. Leu, C. H. Chiu, M. H. Lee, P. C. Chiang, T. L. Wu, J. H. Chia, L. H. Su, A. J. Kuo, and H. C. Lai. 2009. Clinical manifestations, antibiotic susceptibility and molecular analysis of Mycobacterium kansasii isolates from a university hospital in Taiwan. J Antimicrob Chemother 64:511-514.
10. Chaplin, D. D. Overview of the immune response. J Allergy Clin Immunol 125:S3-23.
11. Medzhitov, R., and C. Janeway, Jr. 2000. Innate immunity. N Engl J Med 343:338-344.
12. Bonilla, F. A., and H. C. Oettgen. Adaptive immunity. J Allergy Clin Immunol 125:S33-40.
13. Cooper, M. A., and W. M. Yokoyama. Memory-like responses of natural killer cells. Immunol Rev 235:297-305.
14. Freud, A. G., and M. A. Caligiuri. 2006. Human natural killer cell development. Immunol Rev 214:56-72.
15. Strowig, T., F. Brilot, and C. Munz. 2008. Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. J Immunol 180:7785-7791.
16. Gong, J. H., G. Maki, and H. G. Klingemann. 1994. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8:652-658.
17. Huntington, N. D., C. A. Vosshenrich, and J. P. Di Santo. 2007. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 7:703-714.
18. Lodoen, M. B., and L. L. Lanier. 2005. Viral modulation of NK cell immunity. Nat Rev Microbiol 3:59-69.
19. Backstrom, E., K. Kristensson, and H. G. Ljunggren. 2004. Activation of natural killer cells: underlying molecular mechanisms revealed. Scand J Immunol 60:14-22.
20. Smyth, M. J., E. Cretney, J. M. Kelly, J. A. Westwood, S. E. Street, H. Yagita, K. Takeda, S. L. van Dommelen, M. A. Degli-Esposti, and Y. Hayakawa. 2005. Activation of NK cell cytotoxicity. Mol Immunol 42:501-510.
21. Wiseman, J. C., L. L. Ma, K. J. Marr, G. J. Jones, and C. H. Mody. 2007. Perforin-dependent cryptococcal microbicidal activity in NK cells requires PI3K-dependent ERK1/2 signaling. J Immunol 178:6456-6464.
22. Lanier, L. L. 2005. NK cell recognition. Annu Rev Immunol 23:225-274.
23. Smyth, M. J., Y. Hayakawa, K. Takeda, and H. Yagita. 2002. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2:850-861.
24. Sivori, S., M. Vitale, L. Morelli, L. Sanseverino, R. Augugliaro, C. Bottino, L. Moretta, and A. Moretta. 1997. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 186:1129-1136.
25. Pende, D., S. Parolini, A. Pessino, S. Sivori, R. Augugliaro, L. Morelli, E. Marcenaro, L. Accame, A. Malaspina, R. Biassoni, C. Bottino, L. Moretta, and A. Moretta. 1999. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 190:1505-1516.
26. Cantoni, C., C. Bottino, M. Vitale, A. Pessino, R. Augugliaro, A. Malaspina, S. Parolini, L. Moretta, A. Moretta, and R. Biassoni. 1999. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 189:787-796.
27. Vitale, M., C. Bottino, S. Sivori, L. Sanseverino, R. Castriconi, E. Marcenaro, R. Augugliaro, L. Moretta, and A. Moretta. 1998. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 187:2065-2072.
28. Moretta, A., C. Bottino, M. Vitale, D. Pende, C. Cantoni, M. C. Mingari, R. Biassoni, and L. Moretta. 2001. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19:197-223.
29. Moretta, L., and A. Moretta. 2004. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 23:255-259.
30. Maroof, A., L. Beattie, S. Zubairi, M. Svensson, S. Stager, and P. M. Kaye. 2008. Posttranscriptional regulation of II10 gene expression allows natural killer cells to express immunoregulatory function. Immunity 29:295-305.
31. Ma, L. L., C. L. Wang, G. G. Neely, S. Epelman, A. M. Krensky, and C. H. Mody. 2004. NK cells use perforin rather than granulysin for anticryptococcal activity. J Immunol 173:3357-3365.
32. Biron, C. A., K. B. Nguyen, G. C. Pien, L. P. Cousens, and T. P. Salazar-Mather. 1999. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17:189-220.
33. Vivier, E., J. A. Nunes, and F. Vely. 2004. Natural killer cell signaling pathways. Science 306:1517-1519.
34. Salih, H. R., H. Antropius, F. Gieseke, S. Z. Lutz, L. Kanz, H. G. Rammensee, and A. Steinle. 2003. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102:1389-1396.
35. Cosman, D., J. Mullberg, C. L. Sutherland, W. Chin, R. Armitage, W. Fanslow, M. Kubin, and N. J. Chalupny. 2001. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14:123-133.
36. Djeu, J. Y., K. Jiang, and S. Wei. 2002. A view to a kill: signals triggering cytotoxicity. Clin Cancer Res 8:636-640.
37. Leibson, P. J. 1997. Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity 6:655-661.
38. Wu, J., Y. Song, A. B. Bakker, S. Bauer, T. Spies, L. L. Lanier, and J. H. Phillips. 1999. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285:730-732.
39. Lanier, L. L. 2008. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9:495-502.
40. Wei, S., A. M. Gamero, J. H. Liu, A. A. Daulton, N. I. Valkov, J. A. Trapani, A. C. Larner, M. J. Weber, and J. Y. Djeu. 1998. Control of lytic function by mitogen-activated protein kinase/extracellular regulatory kinase 2 (ERK2) in a human natural killer cell line: identification of perforin and granzyme B mobilization by functional ERK2. J Exp Med 187:1753-1765.
41. Kumar, D., J. Hosse, C. von Toerne, E. Noessner, and P. J. Nelson. 2009. JNK MAPK pathway regulates constitutive transcription of CCL5 by human NK cells through SP1. J Immunol 182:1011-1020.
42. Trotta, R., K. Fettucciari, L. Azzoni, B. Abebe, K. A. Puorro, L. C. Eisenlohr, and B. Perussia. 2000. Differential role of p38 and c-Jun N-terminal kinase 1 mitogen-activated protein kinases in NK cell cytotoxicity. J Immunol 165:1782-1789.
43. Jiang, K., B. Zhong, D. L. Gilvary, B. C. Corliss, E. Hong-Geller, S. Wei, and J. Y. Djeu. 2000. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat Immunol 1:419-425.
44. Chen, X., P. P. Trivedi, B. Ge, K. Krzewski, and J. L. Strominger. 2007. Many NK cell receptors activate ERK2 and JNK1 to trigger microtubule organizing center and granule polarization and cytotoxicity. Proc Natl Acad Sci U S A 104:6329-6334.
45. Trapani, J. A., and M. J. Smyth. 2002. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2:735-747.
46. Lowin, B., M. C. Peitsch, and J. Tschopp. 1995. Perforin and granzymes: crucial effector molecules in cytolytic T lymphocyte and natural killer cell-mediated cytotoxicity. Curr Top Microbiol Immunol 198:1-24.
47. Uellner, R., M. J. Zvelebil, J. Hopkins, J. Jones, L. K. MacDougall, B. P. Morgan, E. Podack, M. D. Waterfield, and G. M. Griffiths. 1997. Perforin is activated by a proteolytic cleavage during biosynthesis which reveals a phospholipid-binding C2 domain. EMBO J 16:7287-7296.
48. Shi, L., R. P. Kraut, R. Aebersold, and A. H. Greenberg. 1992. A natural killer cell granule protein that induces DNA fragmentation and apoptosis. J Exp Med 175:553-566.
49. Quan, P. C., T. Ishizaka, and B. R. Bloom. 1982. Studies on the mechanism of NK cell lysis. J Immunol 128:1786-1791.
50. Neighbour, P. A., and H. S. Huberman. 1982. Sr++-induced inhibition of human natural killer (NK) cell-mediated cytotoxicity. J Immunol 128:1236-1240.
51. Lu, C. C., and J. K. Chen. Resveratrol enhances perforin expression and NK cell cytotoxicity through NKG2D-dependent pathways. J Cell Physiol 223:343-351.
52. Shitrit, D., R. Priess, N. Peled, G. Bishara, D. Shlomi, and M. R. Kramer. 2007. Differentiation of Mycobacterium kansasii infection from Mycobacterium tuberculosis infection: comparison of clinical features, radiological appearance, and outcome. Eur J Clin Microbiol Infect Dis 26:679-684.
53. Wieland, C. W., S. Florquin, J. M. Pater, S. Weijer, and T. van der Poll. 2006. CD4+ cells play a limited role in murine lung infection with Mycobacterium kansasii. Am J Respir Cell Mol Biol 34:167-173.
54. Clayberger, C., and A. M. Krensky. 2003. Granulysin. Curr Opin Immunol 15:560-565.
55. Stenger, S., D. A. Hanson, R. Teitelbaum, P. Dewan, K. R. Niazi, C. J. Froelich, T. Ganz, S. Thoma-Uszynski, A. Melian, C. Bogdan, S. A. Porcelli, B. R. Bloom, A. M. Krensky, and R. L. Modlin. 1998. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282:121-125.
56. Ljunggren, H. G., and K. J. Malmberg. 2007. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 7:329-339.
57. Esin, S., G. Batoni, C. Counoupas, A. Stringaro, F. L. Brancatisano, M. Colone, G. Maisetta, W. Florio, G. Arancia, and M. Campa. 2008. Direct binding of human NK cell natural cytotoxicity receptor NKp44 to the surfaces of mycobacteria and other bacteria. Infect Immun 76:1719-1727.
|